Understanding the cell biology of SARS-CoV-2 endocytosis for COVID-19 drug repurposing: looking beyond chloroquine

Oleg O. Glebov^{1,2}

¹ Institute of Neuroregeneration and Neurorehabilitation, Qingdao University Medical School, Qingdao 266071, Shandong, China.

² Department of Old Age Psychiatry, The Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.

E-mail: oleg.glebov@kcl.ac.uk

Abstract

The quest for the effective treatment against COVID-19 pneumonia caused by the SARS-CoV-2 coronavirus is hampered by the lack of knowledge concerning the basic cell biology of the infection. Given that most viruses use endocytosis to enter the host cell, mechanistic investigation of SARS-CoV-2 infection needs to consider the diversity of endocytic pathways available for SARS-CoV-2 entry in the human lung epithelium. Taking advantage of the well-established methodology of membrane trafficking studies, this research direction allows for rapid characterisation of the key cell biological mechanism(s) responsible for SARS-CoV-2 infection. Furthermore, 11 clinically approved generic drugs are identified as potential candidates for repurposing as blockers of several potential routes for SARS-CoV-2 endocytosis. More broadly, the paradigm of targeting a fundamental aspect of human cell biology to protect against infection may be advantageous in the context of future pandemic outbreaks.

Introduction

At the time of writing this piece, the pandemic of the atypical pneumonia COVID-19 caused by a novel coronavirus SARS-CoV-2 has spread to 209 countries and territories in the world, with 1,297,704 active cases and 71,282 deaths, and continuing (<https://www.worldometers.info/coronavirus/>). This current epidemiological, economical and potentially political disaster-in-the-making follows in the wake of earlier outbreaks of respiratory infections SARS and MERS, also caused by coronaviruses¹. There is currently no known cure for COVID-19, and available medical treatment is largely limited to alleviation of the respiratory dysfunction associated with the severe course of the disease.

As a result of this, an enormous effort across biomedical sciences is mounting to develop therapeutic means of treating COVID-19. One key area of this development is vaccination. As of March 20, there were 2 candidate vaccines in clinical evaluation, with as many as 42 in pre-clinical stage². Yet necessities of the research and development process dictate that none of the above – in the best possible scenario – will be clinically available earlier than in 18 months' time³. Given the unprecedented scale of the current outbreak, there is immense pressure to find faster and cheaper therapeutic solutions to this rapidly worsening global health crisis.

There is a broad agreement that perhaps the best way to produce an affordable treatment on a faster timescale is to repurpose existing drugs, and much interest is directed this way, especially focusing on drugs with previously demonstrated antiviral capabilities⁴. However, lack of the basic understanding of the cell biology of SARS-CoV-2 infection limits the efficacy of such an approach. Although recent years have yielded some insight into the cell biology of the related human virus SARS-CoV, and the two viruses may bind to the same surface receptor protein ACE2⁵⁻⁸, their genomes still differ by 20%⁸, and the associated epidemiological picture is very different indeed. Furthermore, preliminary evidence questions ACE2 expression in the lung epithelium⁹, suggesting that other surface receptors may be involved in SARS-CoV-2 infection¹⁰. The resulting gap in knowledge forms a major obstacle on the road towards effective drug re-purposing for treating COVID-19.

The many unknowns of SARS-CoV-2 cell entry

The critical step in any viral infection involves penetration of the viral particles into the cytosol; to this end, most viruses take advantage of the endocytic membrane trafficking of the host cell¹¹. While the canonical endocytic pathways in mammalian cells involve

budding of clathrin-coated vesicles through the action of a large GTPase dynamin, there are also multiple pathways of non-canonical endocytosis such as caveolae, flotillin-1-associated endocytosis, CLIC/GEEC endocytosis, and macropinocytosis¹², and viruses have been shown to use all of these¹¹ (**Figure 1**). Therefore, prevention of endocytic viral entry may be a promising therapeutic strategy to treat viral infections.

As far as coronaviruses are concerned, current evidence suggests that the mode of entry can vary between viruses and host cell types, and can include clathrin-dependent endocytosis¹³, caveolae¹⁴, and clathrin-and caveolae-independent mechanism involving lipid rafts^{15,16}. Fusion at the cell surface, while proposed as a potential entry mechanism⁵, was not directly demonstrated. Both SARS-CoV and SARS-CoV-2 appear to require endocytosis in cultured cell lines^{6,15-17}, and SARS-CoV may be endocytosed via more than one pathway depending on the cell line^{15,17}. However, there is little knowledge regarding the details of the epidemiologically relevant mode of viral entry, i.e. in the human lung. It is therefore imperative to consider SARS-CoV-2 endocytic trafficking in context of the correct host cell type.

Preliminary evidence suggests that infection with SARS-CoV-2 may begin in the upper respiratory tract, e.g. in the nasal epithelium, which expresses the highest levels of SARS-CoV-2 receptors¹⁸. The most significant morbidity and indeed mortality, however, appears to be associated with a further, severe stage of the disease, when infection spreads to the lower airways of the lung, resulting in respiratory failure, and possibly multi-organ failure due to cytokine storm¹⁹. Although the histopathology data is still scant, two case studies and preliminary findings from a primate disease model indicate that the lower airways SARS-CoV-2 infection may specifically affect the alveolar epithelial cells termed pneumocytes²⁰⁻²². Clearly, blockade of the SARS-CoV-2 entry at either of these stages is likely to yield considerable therapeutic benefits.

Endocytic pathways in respiratory epithelial cells

To establish which endocytic pathways are likely to operate in nasal epithelial cells and pneumocytes, some clues can be gleaned from the local expression profile for the key endocytic proteins as evidenced by the Human Protein Atlas (<https://www.proteinatlas.org/>). Nasal epithelial cells abundantly express a wide variety of endocytic markers, suggesting the presence of multiple active pathways, in agreement with ultrastructural evidence²³. Conversely, pneumocytes show a more restricted expression pattern, with some key proteins associated with conventional endocytosis either low or missing. Importantly, a large GTPase, dynamin, which is

required for endocytosis through clathrin-coated vesicles and caveolae, is abundant in nasal epithelium but undetectable in pneumocytes. In contrast, there are medium-to-high expression levels of proteins involved in macropinocytosis, such as CtBP1&2 and Pak1. Therefore, macropinocytosis may be an important endocytic pathway in pneumocytes.

The potentially distinct endocytic profile of upper and lower airways is reflected in the relevant infection mechanisms for known pathogens. Upper respiratory epithelium can be infected by numerous airborne pathogens through multiple pathways of dynamin-dependent and independent endocytosis¹¹. Conversely, pneumocyte infection is much less well understood; however, entry through macropinocytosis has been consistently demonstrated for airborne bacterial and viral pathogens such as *Mycobacterium tuberculosis*²⁴, *Francisella tularensis*²⁵, Influenza A virus²⁶, adenovirus Ad35²⁷ and *Haemophilus influenzae*²⁸, as well as for various nanoparticles^{29,30}. Intriguingly, macropinocytosis in an alveolar epithelial cell line is upregulated by water-pipe smoke condensate, suggesting a possible mechanism underlying association of COVID-19 morbidity with smoking³¹.

Taken together, the above evidence suggests that SARS-CoV-2 may employ distinct endocytic pathways for cell entry in the upper and lower respiratory tract (**Figure 1**). What are these pathways? To address this question directly, we need to investigate the cell biology of SARS-CoV-2 endocytosis in detail.

Potential experimental model for investigating the key events of SARS-CoV-2 cell entry *in vitro*

A suitable starting model for initial investigation of SARS-CoV-2 endocytosis can involve established immortalised cell lines derived from the respiratory tract epithelium (<https://www.atcc.org/~media/PDFs/Cancer%20and%20Normal%20cell%20lines%20tables/Lung%20cancer%20and%20normal%20cell%20lines.ashx>). These lines provide several key methodological advantages: they are well-characterised, easy to maintain using standard cell culture protocols, and retain the key characteristics of the primary cell type of origin. For emulation of the respiratory tract environment, the cell lines can be grown in an air-liquid Interface culture as described before^{32,33}.

Immortalised cell cultures offer a simple and cost-effective platform for investigation of cell biology. There are, however, important caveats associated with immortalised cell cultures *in vitro*, which need addressing and further validation. One key consideration is

expression profile, which in a cell line may be different from that in the original tissue. This can be especially relevant with regards to membrane trafficking, where discrepancy in expression of certain key proteins may affect the organisation of the whole network: for example, the lung cell line A549 can express multiple isoforms of dynamin³⁴, which is not the case in pneumocytes in human lung tissue.

As a result of this, any findings arising from the cell lines will need to be investigated further in a more expensive, but clinically relevant system of primary cells. Cell preparations for both lower and upper respiratory tract are commercially available^{35,36}. Preliminary evidence shows that such systems can be efficiently infected with SARS-CoV-2³⁷. Alternatively, cells can be directly obtained from human subjects, e.g. nasal epithelium, or alveolar epithelial cells can be isolated from surgically resected lung tissue material³⁸. Regardless of that, validation of findings in primary cells will be a key step in investigation.

Experimental interrogation of SARS-CoV-2 membrane trafficking

Investigation of membrane trafficking of SARS-CoV-2 requires a probe that can adequately recapitulate the intracellular itinerary of the virus. Using active, clinically isolated live virus samples would of course allow a closest approximation. However, a major drawback of this approach is a highly infectious nature of the virus, necessitating the use of a Biosafety Level 3 laboratory. An alternative approach would involve pseudoviruses, combining viral surface proteins responsible for cell receptor binding. The lack of SARS-CoV-2 genetic material renders them incapable of replication, allowing work in a Biosafety Level 2 laboratory. Pseudoviruses have been successfully used before to investigate trafficking of SARS-CoV and MERS-CoV^{5,15}, and a SARS-CoV-2 pseudovirus model has been recently published^{6,7}.

For infection, the viral probe will be added to the cells for different lengths of time. In order to determine the endocytic pathway(s) involved in SARS-CoV-2 endocytosis, one can employ standard methods of multi-colour fluorescence immunocytochemistry, light microscopy and colocalisation analysis. The proportion of the internalised virus colocalising with the classical markers of membrane trafficking compartments will indicate the intracellular itinerary of the virus³⁹. For this approach, multiple well-characterised antibody markers for intracellular compartments *e.g.* early endosomes, late endosomes and lysosomes are available.

For a more detailed investigation of the endocytic route of the virus,, viral infection can be combined with uptake of typical cargoes for different endocytic pathways. This

approach would allow tracking of the virus in relation to other endocytic pathways, and to also to investigate the effect of viral infection on the general membrane trafficking network of the host cell. Suitable cargo molecules include transferrin for clathrin-dependent endocytosis⁴⁰, Cholera Toxin B subunit for caveolae⁴¹, and dextran for fluid-phase macropinocytosis and flotillin-dependent endocytosis⁴².

What is the relative contribution of different endocytic pathways to SARS-CoV-2 infection? To address this question, loss-of-function analysis can be performed, involving knockdown of the key regulatory proteins for different endocytic pathways, e.g. dynamin 2, caveolin-1, flotillin-1, and CtBP^{12,41} (**Figure 1**). The resulting findings can be further corroborated using available pharmacological blockers of endocytic pathways, including Dynasore and Pitstop for clathrin-dependent endocytosis, nystatin for caveolae, methyl-beta cyclodextrin for dynamin-independent endocytosis, and amiloride for macropinocytosis. However, care must be exercised in interpretation of these results due to the off-target effects of these agents, in which endocytic pathways other than the target pathway may be inhibited^{43–45}.

Repurposing previously approved drugs for blocking SARS-CoV-2 endocytosis

Once the endocytic route of SARS-CoV-2 in primary lung epithelial cells has been established, this insight can be immediately capitalised upon for translational needs. Specifically, a cell-based model of SARS-CoV-2 infection³⁷ will naturally lend itself to establishment of a screening platform for rapid re-purposing of approved drugs, which in this case will aim to identify compounds capable of blocking or hindering SARS-CoV-2 entry. There is already vivid interest in chloroquine and hydroxychloroquine, two related drugs that may block viral entry through endosomal acidification (**Figure 1**), although evidence for their effectiveness is currently scant and side effects are a major concern⁴⁶. Of note, compounds showing even partial blockade of SARS-CoV-2 endocytosis may be of value, as clinical evidence suggests that viral load may correlate with the severity of the disease progression – in other words, the fewer virus particles that get into the cells, the better the prognosis.

Large-scale screening of this sort will require considerable time and effort; given the dynamic development of the pandemics, a short-term screening of a limited number of candidate drugs is highly warranted. To this end, the range of candidates can be limited to the following 11 approved drugs previously shown to block different pathways of endocytosis (**Table 1, Figure 1**). Additionally, a cholesterol chelating agent beta methyl cyclodextrin, used as a carrier to enhance bioavailability in drug formulations and

generally recognized as safe by the Food and Drug Administration (USA), blocks multiple endocytic pathways in a variety of cell types.

Importantly, 5 out of 11 drugs (chlorpromazine, nystatin, amiloride, vinblastine, itraconazole) are on the World Health Organization's List of Essential Medicines, ensuring their wide availability across the world. Also, several have been tested (or are being tested) for topical delivery into the respiratory tract (**Table 1**). These factors will be favourable for rapid integration of the successful drugs into global clinical practice – a key consideration given the current epidemiological forecast.

Conclusion

Despite frenzied efforts to find effective treatments for COVID-19, very little is currently known about the fundamental cell biology of the SARS-CoV-2 infection. The pivotal event underpinning SARS-CoV-2 infection is likely endocytosis of viral particles, therefore blockade of this process may provide for a major therapeutic breakthrough. The well-developed tools of membrane trafficking research can be readily applied to rapidly characterise the endocytic route of virus entry in a cell-based model of disease, providing a key insight into the disease mechanism (**Figure 1**). Crucially, the same model can be used as a screening platform for rapid repurposing of existing approved drugs as blockers of SARS-CoV-2 entry (**Table 1**).

The generalised strategy of targeting the membrane trafficking of the host cell biology to prevent viral infection holds great promise for future therapeutic applications, considering the existence of other zoonotic coronaviruses capable of binding to human cells⁴⁷. More broadly, rapid repurposing of approved drugs in cell-based screening platforms is poised to play an instrumental role in future-proofing global healthcare against the interspecies transmission events. In the age of unparalleled spending on pharmaceutical research and development, humankind cannot afford to neglect one of its most valuable allies in the fight against the current and the future pandemics – the basic foundations of human cell biology.

Acknowledgements

E. Barker, Y. Kainov, P. Mozerov, G. Ryzhakov, D. Madera, P. Lidsky, and M. Spivakov are thanked for their helpful comments on the manuscript.

Competing interests statement

None.

References

1. Park, M., Thwaites, R. S. & Openshaw, P. J. M. COVID-19: Lessons from SARS and MERS. *Eur. J. Immunol.* **50**, 308–311 (2020).
2. WHO | Coronavirus disease (COVID-2019) R&D. *WHO* (2020).
3. Coronavirus vaccine: when will it be ready? | World news | The Guardian. Available at: <https://www.theguardian.com/world/2020/apr/01/coronavirus-vaccine-when-will-it-be-ready-covid-19>. (Accessed: 1st April 2020)
4. Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov. Ther.* **14**, 58–60 (2020).
5. Lu, L. *et al.* Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nat. Commun.* **5**, 3067 (2014).
6. Ou, X. *et al.* Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat. Commun.* **11**, 1620 (2020).
7. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* (2020). doi:10.1016/J.CELL.2020.02.052
8. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).
9. Hikmet, F., Mear, L., Uhlen, M. & Lindskog, C. The protein expression profile of ACE2 in human tissues. *bioRxiv* 2020.03.31.016048 (2020). doi:10.1101/2020.03.31.016048
10. Wang, K. *et al.* SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. *bioRxiv* 2020.03.14.988345 (2020). doi:10.1101/2020.03.14.988345
11. Mercer, J., Schelhaas, M. & Helenius, A. Virus entry by endocytosis. *Annu. Rev. Biochem.* **79**, 803–33 (2010).
12. Doherty, G. J. & McMahon, H. T. Mechanisms of endocytosis. *Annu. Rev. Biochem.* **78**, 857–902 (2009).
13. Milewska, A. *et al.* Entry of Human Coronavirus NL63 into the Cell. *J. Virol.* **92**, (2018).
14. Szczepanski, A. *et al.* Canine respiratory coronavirus employs caveolin-1-mediated pathway for internalization to HRT-18G cells. *Vet. Res.* **49**, 55 (2018).
15. Wang, H. *et al.* SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res.* **18**, 290–301 (2008).
16. Lu, Y., Liu, D. X. & Tam, J. P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. *Biochem. Biophys. Res. Commun.* **369**, 344–349 (2008).
17. Inoue, Y. *et al.* Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail Deleted. *J. Virol.* **81**, 8722–8729 (2007).
18. Sungnak, W., Huang, N., Bécavin, C., Berg, M. & Network, H. L. B. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways. (2020).
19. Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet (London, England)* **395**, 1033–1034 (2020).
20. Tian, S. *et al.* Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. *J. Thorac. Oncol.* (2020). doi:10.1016/J.JTHO.2020.02.010
21. Zhang, H. *et al.* Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. *Ann. Intern. Med.* (2020). doi:10.7326/M20-0533
22. Rockx, B. *et al.* Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model. *bioRxiv* 2020.03.17.995639 (2020). doi:10.1101/2020.03.17.995639
23. Bannister, L. H. & Dodson, H. C. Endocytic pathways in the olfactory and vomeronasal epithelia of the mouse: Ultrastructure and uptake of tracers. *Microsc. Res. Tech.* **23**, 128–141 (1992).
24. García-Pérez, B. E., Mondragón-Flores, R. & Luna-Herrera, J. Internalization of Mycobacterium tuberculosis by macropinocytosis in non-phagocytic cells. *Microb. Pathog.* **35**, 49–55 (2003).
25. Bradburne, C. E. *et al.* Temporal Transcriptional Response during Infection of Type II Alveolar Epithelial Cells with *Francisella tularensis* Live Vaccine Strain (LVS) Supports a General Host Suppression and Bacterial Uptake by Macropinocytosis. *J. Biol. Chem.* **288**, 10780–10791 (2013).
26. de Vries, E. *et al.* Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. *PLoS Pathog.* **7**, e1001329 (2011).
27. Kalin, S. *et al.* Macropinocytotic Uptake and Infection of Human Epithelial Cells with Species B2 Adenovirus Type 35. *J. Virol.* **84**, 5336–5350 (2010).
28. López-Gómez, A. *et al.* Host cell kinases, $\alpha 5$ and $\beta 1$ integrins, and Rac1 signalling on the microtubule cytoskeleton are important for non-typable *Haemophilus influenzae* invasion of respiratory epithelial cells. *Microbiology* **158**, 2384–2398 (2012).
29. dos Santos, T., Varela, J., Lynch, I., Salvati, A. & Dawson, K. A. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. *PLoS One* **6**, e24438 (2011).
30. Sipos, A., Kim, K.-J., Sioutas, C. & Crandall, E. D. Evidence for Nanoparticle-Induced Lysosomal Dysfunction in Lung Adenocarcinoma (A549) Cells. *Int. J. Mol. Sci.* **20**, 5253 (2019).
31. Vardavas, C. & Nikitara, K. COVID-19 and smoking: A systematic review of the evidence. *Tob. Induc.*

- Dis.* **18**, (2020).
32. Wu, J. *et al.* Characterization of air-liquid interface culture of A549 alveolar epithelial cells. *Brazilian J. Med. Biol. Res. = Rev. Bras. Pesqui. medicas e Biol.* **51**, e6950 (2017).
 33. Kreft, M. E. *et al.* The Characterization of the Human Nasal Epithelial Cell Line RPMI 2650 Under Different Culture Conditions and Their Optimization for an Appropriate in vitro Nasal Model. *Pharm. Res.* **32**, 665–679 (2015).
 34. Reis, C. R., Chen, P.-H., Bendris, N. & Schmid, S. L. TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 504–509 (2017).
 35. Huang, S., Wiszniewski, L., Constant, S. & Roggen, E. Potential of in vitro reconstituted 3D human airway epithelia (MucilAir™) to assess respiratory sensitizers. *Toxicol. Vitro.* **27**, 1151–1156 (2013).
 36. Akimoto, M., Hayashi, J.-I., Nakae, S., Saito, H. & Takenaga, K. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. *Cell Death Dis.* **7**, e2057–e2057 (2016).
 37. Pizzorno, A. *et al.* Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. *bioRxiv* 2020.03.31.017889 (2020). doi:10.1101/2020.03.31.017889
 38. Ehrhardt, C., Kim, K.-J. & Lehr, C.-M. Isolation and Culture of Human Alveolar Epithelial Cells. in *Human Cell Culture Protocols* 207–216 (Humana Press). doi:10.1385/1-59259-861-7:207
 39. Kumari, S., MG, S. & Mayor, S. Endocytosis unplugged: multiple ways to enter the cell. *Cell Res.* **20**, 256–275 (2010).
 40. Glebov, O. O., Tigaret, C. M., Mellor, J. R. & Henley, J. M. Clathrin-Independent Trafficking of AMPA Receptors. *J. Neurosci.* **35**, 4830–4836 (2015).
 41. Hansen, C. G. & Nichols, B. J. Molecular mechanisms of clathrin-independent endocytosis. *J. Cell Sci.* **122**, 1713–21 (2009).
 42. Glebov, O. O., Bright, N. A. & Nichols, B. J. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. *Nat. Cell Biol.* **8**, 46–54 (2006).
 43. Park, R. J. *et al.* Dynamin triple knockout cells reveal off target effects of commonly used dynamin inhibitors. *J. Cell Sci.* **126**, 5305–12 (2013).
 44. Dutta, D., Williamson, C. D., Cole, N. B. & Donaldson, J. G. Pitstop 2 is a potent inhibitor of clathrin-independent endocytosis. *PLoS One* **7**, e45799 (2012).
 45. Vercauteren, D. *et al.* The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls. *Mol. Ther.* **18**, 561–569 (2010).
 46. Owens, B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. *Lancet Rheumatol.* **0**, (2020).
 47. Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat. Microbiol.* **5**, 562–569 (2020).
 48. Otomo, M. *et al.* Some Selective Serotonin Reuptake Inhibitors Inhibit Dynamin I Guanosine Triphosphatase (GTPase). *Biol. Pharm. Bull.* **31**, 1489–1495 (2008).
 49. Takahashi, K. *et al.* Suppression of dynamin GTPase activity by sertraline leads to inhibition of dynamin-dependent endocytosis. *Biochem. Biophys. Res. Commun.* **391**, 382–7 (2010).
 50. HERXHEIMER, H. Antihistamines in bronchial asthma. *Br. Med. J.* **2**, 901–5 (1949).
 51. Sharma, R. K., Sehgal, S., Sachdeva, N., Kumar, R. & Gupta, A. Direct Engagement of TLR9 Ligand with T Helper Cells Leads to Cell Proliferation & Up-regulation of Cytokines. *Immunol. Invest.* **48**, 79–95 (2019).
 52. McKENDRICK, G. D. & MEDLOCK, J. M. Pulmonary moniliasis treated with nystatin aerosol. *Lancet (London, England)* **1**, 621–2 (1958).
 53. Tomkiewicz, R. P. *et al.* Amiloride Inhalation Therapy in Cystic Fibrosis: Influence on Ion Content, Hydration, and Rheology of Sputum. *Am. Rev. Respir. Dis.* **148**, 1002–1007 (1993).
 54. Lin, H.-P. *et al.* Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs. *Br. J. Pharmacol.* **175**, 3640–3655 (2018).
 55. Morgan, E. H. & Iacopetta, B. J. VINBLASTINE BUT NOT OTHER MICROTUBULE INHIBITORS BLOCK TRANSFERRIN ENDOCYTOSIS AND IRON UPTAKE BY RETICULOCYTES. *Clin. Exp. Pharmacol. Physiol.* **14**, 119–126 (1987).
 56. Inhaled Itraconazole Fast-Tracker for Allergic Bronchopulmonary Aspergillosis in Asthma. Available at: <https://www.pulmonologyadvisor.com/home/topics/asthma/inhaled-itraconazole-fast-tracked-for-allergic-bronchopulmonary-aspergillosis-in-asthma/>. (Accessed: 1st April 2020)
 57. Itraconazole Inhalation Receives IND Approval for Phase 2 Clinical Trial. Available at: <https://www.pharmacytimes.com/resource-centers/asthma/itraconazole-inhalation-receives-ind-approval-for-phase-2-clinical-trial>. (Accessed: 3rd April 2020)
 58. Irie, T. & Uekama, K. Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation. *J. Pharm. Sci.* **86**, 147–162 (1997).

Name	Primary Indication	Potential direct delivery into respiratory tract	Endocytic pathway affected
Chlorpromazine	Anti-psychotic		Clathrin, other ⁴⁵
Fluvoxamine	Anti-depressant		Dynamin ⁴⁸
Sertraline	Anti-depressant		Dynamin ⁴⁹
Promethazine	Anti-histamine	Aerosol ⁵⁰	Clathrin ⁵¹
Nystatin	Anti-fungal	Aerosol ⁵²	Caveolae ⁴⁵
Amiloride	Diuretic	Inhalation ⁵³	Macropinocytosis
Vinblastine	Microtubule formation inhibitor		Macropinocytosis ⁵⁴ , Clathrin ⁵⁵
Itraconazole	Anti-fungal	Inhaled powder (Phase 2) ^{56,57}	Macropinocytosis ⁵⁴
Flubendazole	Anti-helminthic		Macropinocytosis ⁵⁴
Terfenadine	Histamine H ₁ -receptor antagonist		Macropinocytosis ⁵⁴
Imipramine	Anti-depressant		Macropinocytosis ⁵⁴
Beta-methyl cyclodextrin	Bioavailability enhancer	Intranasal ⁵⁸	Multiple

Table 1. Previously approved drugs to be tested for blockade of SARS-CoV-2 endocytosis in respiratory epithelium.

Figure 1. A simplified representation of endocytic pathways potentially involved in internalization of SARS-CoV-2. Selected key structural and regulatory proteins are shown graphically or mentioned by name. The names of the prospective drug blockers are italicised. Arrows indicate progression of the virus through the endosomal system.